Friday, February 24, 2017 10:30:39 AM
This article about cancer makes this very clear:
Cancer: Cure vs. Remission
By Ed Zimney, MD
We’re often asked about the meaning of certain terms that are used in talking about cancer. Because cancer is so varied and its treatment so complex, the list of cancer-related terms is enormous. For that reason, the National Cancer Institute, part of the National Institutes of Health (NIH), maintains a thorough dictionary of cancer terms, and each of the HealthTalk cancer networks also contains a glossary, such as this breast cancer glossary.
One area of particular interest is the question of the difference between cancer cure and cancer remission. Doctors almost never use the term cure; rather, they usually talk about remission.
Complete remission means that there are no symptoms and no signs that can be identified to indicate the presence of cancer. However, even when a person is in remission, there may be microscopic collections of cancer cells that cannot be identified by current techniques. This means that even if a person is in remission, they may, at some future time, experience a recurrence of their cancer.
Partial remission means that a large percentage of the signs and symptoms of cancer are gone, but some still remain. Complete remission would therefore be better than partial remission because with partial remission the chances of recurrence are higher.
Doctors will sometimes refer to 5-year cure rate or a 10- or more year cure rate. What they really mean by this is a 5- or more year remission rate. The longer the remission time lasts, the greater the possibility that the cancer actually has been cured, but there are cases of cancer recurrence many, many years after remission begins. So if the doctor says there is a 95 percent 5-year cure/remission rate for a particular cancer, it means that after five years, 95 percent of people with that cancer will still be in remission (meaning that you have an extremely high likelihood of not having a recurrence for at least five years). With people living longer and longer, doctors can now often give remission rates for 10, 15 or even 20 years. In many ways, the approach to most cancer treatment is to make it a chronic disease that lasts for many years.
So can we ever really talk about a cancer cure? In general, the answer is no. Practically speaking, however, the odds of a recurrence may be so low that the person is essentially cured. To put it another way, depending on your age, the doctor may tell you that the odds of your dying of cancer are lower than are your odds of dying of something else. Let’s say the doctor says there is an 80 percent remission rate for your cancer at 10 years. But at your age and health status, there is a 90 percent chance of death due to cardiovascular disease within that 10-year time. You could say your cancer was cured, but it wouldn’t necessarily be a very joyous occasion.
http://www.everydayhealth.com/columns/zimney-health-and-medical-news-you-can-use/cancer-cure-vs-remission/
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM

